RxDoctor Payments Data

Kerstin Uy, MD

Psychiatry · Pawtucket, RINPI 1922088020

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 28.9% of the total.

$555in general payments, 2019–2025

Across 15 payments — averaging $36.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$161
  • Johnson & Johnson$146
  • E.r. Squibb & Sons, L.L.C.$121
  • Axsome Therapeutics, Inc.$39
  • Teva Pharmaceuticals USA, Inc.$36
  • Supernus Pharmaceuticals, Inc.$20
  • plus $32 from 2 others

What the payments were for

  • Food & beverage$555100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$555 in reported general payments places this provider in the 75th percentile of 209 psychiatry providers in Rhode Island.

See all psychiatry providers in Rhode Island

Medicare billing

Part B allowed, 2024
$14,060
Medicare patients
53
Services billed
128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate41$313,644
Invega SustennaPaliperidone Palmitate81$206,861
Invega TrinzaPaliperidone Palmitate26$199,949
Abilify MaintenaAripiprazole53$137,506
AustedoDeutetrabenazine21$121,064
RexultiBrexpiprazole41$57,816
VraylarCariprazine Hcl26$35,271
Clozapine367$24,873
Effexor XrVenlafaxine Hcl11$23,502
Paliperidone ErPaliperidone82$14,906
Risperidone ErRisperidone Microspheres14$14,193
Asenapine Maleate31$9,899
TrintellixVortioxetine Hydrobromide20$9,126
Aripiprazole153$9,045
Chlorpromazine Hcl39$8,842

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$146$406,810107 claims
Neurocrine Biosciences, Inc.Ingrezza$161$313,64441 claims
Teva Pharmaceuticals USA, Inc.Austedo$36$121,06421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 209 psychiatry providers in Rhode Island.

Other psychiatry in Pawtucket

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →